

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

---

# Pharmacogenomics in Tailoring First-Line Therapy for Breast Cancer: PharmGKB Database Insights

---

PREPRINT

**Murilo Porfírio de Aguiar<sup>1</sup>**

<sup>1</sup> Federal Unniversity of Triangulo Mineiro, Brazil.

November 28, 2023.

## ABSTRACT

This study delves into the role of pharmacogenomics in optimizing first-line breast cancer treatments, leveraging insights from the PharmGKB database. It emphasizes the importance of understanding genetic variations and their influence on the efficacy and side effects of key drugs like Letrozole, Anastrozole, Tamoxifen, Trastuzumab, and Pertuzumab. By analyzing these drugs in the context of genetic profiles, the research highlights the necessity of incorporating genetic testing into treatment planning. The findings underscore the potential of pharmacogenetics to personalize therapy, aiming to improve outcomes and reduce adverse reactions in breast cancer patients. This approach marks a significant stride towards tailored cancer treatments, underscoring the need for continued research in this field.

## INTRODUCTION

Breast cancer is a major global health concern, with age-standardized incidence and mortality rates estimated at 37.4 and 13.2 per 100,000 women, respectively [1]. Recent advances in personalized medicine have significantly increased interest in pharmacogenetics, a field that examines how genetic variations influence an individual's response to medications [2, 3]. This area is particularly critical in breast cancer treatment, where the effectiveness of therapy is often undermined by drug resistance and treatment-related toxicities [1].

The goal of pharmacogenetics is to identify individuals who are at an increased risk of experiencing toxicity at conventional doses of chemotherapeutic agents. Genetic variations in genes responsible for drug metabolism, transport, or targeting are known to contribute to the interindividual variability observed in both the efficacy and toxicity of drug treatments [4]. Of particular note are the polymorphisms in the CYP2D6 gene, which have been linked to the metabolism and clinical efficacy of tamoxifen, a cornerstone in the pharmacological management of breast cancer [1].

In the realm of first-line breast cancer treatments, drugs such as letrozole, anastrozole, tamoxifen, trastuzumab, and pertuzumab are commonly employed. These agents have

44 demonstrated substantial effectiveness; for instance, letrozole has been shown to offer  
45 superior quality-adjusted survival rates compared to tamoxifen in a large-scale study  
46 involving over 900 patients with metastatic breast cancer [5]. The inclusion of these drugs in  
47 this integrative review reflects their widespread use and proven effectiveness in managing  
48 breast cancer.

49

50 The PharmGKB database serves as an extensive resource that compiles and curates  
51 knowledge on the impact of genetic variations on drug responses. This database gathers,  
52 curates, and disseminates information on clinically relevant gene-drug interactions and  
53 genotype-phenotype correlations [2, 3]. The application of PharmGKB in this integrative  
54 review provides a robust basis for examining how pharmacogenetics is being integrated into  
55 the personalization of first-line therapies for breast cancer.

56

57 This review endeavors to contribute to the scientific community by offering an analysis of  
58 how pharmacogenetics can be utilized to predict patient responses to first-line medications in  
59 breast cancer therapy, taking into account genetic variations and their effects on drug  
60 metabolism and efficacy. A more comprehensive understanding of these mechanisms can  
61 lead to the development of more effective and personalized treatment strategies for breast  
62 cancer.

63

## 64 **METHODOLOGY**


65

66 This study was formulated to answer the question: "How is pharmacogenomics applied to  
67 personalize first-line therapies in breast cancer treatment?" We undertook an integrative  
68 review of the PharmGKB, an international pharmacogenetics database, focusing on five  
69 primary breast cancer drugs: Letrozole, Anastrozole, Tamoxifen, Trastuzumab, and  
70 Pertuzumab. These drugs were selected based on their widespread use and demonstrated  
71 effectiveness in breast cancer therapy. Each plays a vital role in treatment, and their  
72 therapeutic responses may be affected by genetic variances. For each medication, we  
73 gathered all relevant "Clinical Annotations," particularly focusing on the gene, the variant,  
74 and the characteristics of carriers of each allele. We then collected "Variant Annotations" for  
75 all variants referenced in the clinical citations. Clinical annotations without corresponding  
76 variant information were excluded. The evidence level for each variant's data and the  
77 demographic origin of each study were also reviewed.

78

79 Through this methodology, we identified 68 clinical annotations related to key first-line drugs  
80 for breast cancer in the PharmGKB database. Pertuzumab, a monoclonal antibody used in  
81 HER2-Positive breast cancer, was the only drug without clinical data in the database. For  
82 each clinical annotation, we verified the presence of "variant annotations," which detail the  
83 genomic location of the variant, how it alters the genetic sequence, and its potential impact on  
84 gene function. Nine clinical annotations lacking such details were omitted. Additionally, 3  
85 clinical annotations were removed due to data redundancy, resulting in a total of 12 clinical  
86 annotations being excluded and 56 deemed eligible in the selection and eligibility phase.  
87 During the inclusion phase, each eligible clinical annotation was rigorously analyzed to rule

88 out data without sufficient statistical support or consideration of ethnic genetic differences.  
 89 Consequently, 44 clinical annotations were further excluded, leaving 12 for inclusion in this  
 90 review. Notably, none of the studies involving Trastuzumab met our criteria, as illustrated in:  
 91



92  
 93  
 94  
 95

**Figure 1.** Flowchart of Study Search and Selection.

96

97

98

## 99 RESULTS

100

101 The integrative review on the application of pharmacogenetics in the treatment of breast  
102 cancer with first-line drugs has revealed significant findings. It has been observed that  
103 specific genetic variations in patients impact the efficacy and side effects of the drugs  
104 Letrozole, Anastrozole, and Tamoxifen.

105

106 For Letrozole, genotypes in various genes such as CYP19A1, CYP2A6, ESR1, and ESR2  
107 have been identified as influencing the risk of bone density loss and the drug's metabolization  
108 rate. This information is crucial for dose adjustment and predicting treatment response in  
109 breast cancer patients.

110

111 In the case of Anastrozole, the UGT1A4 rs3732218 genetic variant has been shown to affect  
112 the drug's glucuronidation. This indicates variability in the drug's elimination from the body,  
113 which can influence both its efficacy and the incidence of side effects.

114

115 Regarding Tamoxifen, variations in the CYP2D6, ABCC2, ESR1, ESR2 genes, and a non-  
116 coding region have been demonstrated to significantly impact cancer recurrence, bone  
117 fracture risks, and alterations in cholesterol and triglyceride levels. These findings underscore  
118 the importance of considering the genetic profile in the selection and monitoring of  
119 Tamoxifen treatment.

120

121 **Table 1.** Pharmacogenetic Correlations in Breast Cancer Treatment.

122

Drug	Gene / Variant	Annotation description	Authors
Letrozol	CYP19A1 / rs6493497	In breast cancer treatment, women carrying the AA genotype may experience a heightened risk of bone density loss when treated with exemestane and letrozole. This risk contrasts with those possessing AG and GG genotypes, who typically exhibit a reduced risk.	Liewei et al. [6]
	CYP2A6 / CYP2A6*1	Patients with dual copies of the CYP2A6*1 allele or a combination of *1 and *46 alleles tend to metabolize letrozole at an accelerated rate compared to individuals with other distinct genetic combinations. This rapid metabolism stands in contrast to that observed in patients with allele combinations including *2, *4, *7, *9, *12, *17, among others.	Desta Z et al. [7]
	ESR1 / rs9322335	Women with breast cancer and the CC or CT genotypes are likely to have a diminished risk of bone mineral	Steffi et al. [8]

		density loss when undergoing treatment with letrozole and/or exemestane, unlike those with the TT genotype.	
	ESR1 / rs4870061	In breast cancer patients, those with CC or CT genotypes may experience a lower rate of bone density loss when treated with letrozole, whether or not combined with exemestane, in contrast to individuals with the TT genotype.	Steffi et al. [8]
	ESR2 / rs10140457	Women diagnosed with breast cancer who have the AC genotype might face a reduced risk of bone density loss when treated with letrozole, unlike those carrying the CC genotype. It's noteworthy that women with the AA genotype were not included in this particular study.	Steffi et al. [8]
Anastrozole	UGT1A4 / rs3732218	Patients carrying the AA or AG genotypes are likely to show decreased glucuronidation of anastrozole compared to those with the GG genotype, as demonstrated by in vitro studies. Efficient glucuronidation is vital for the elimination of xenobiotics, including anastrozole.	Koroth et al. [9]
Tamoxifen	CYP2D6 / CYP2D6*1	The presence of the CYP2D61 allele, identified as a normal-function allele, is linked to a decreased likelihood of recurrence and improved event-free survival in patients undergoing tamoxifen treatment for breast cancer. This association is particularly notable when the CYP2D61 allele is combined with other normal metabolizer alleles, as opposed to combinations including null or reduced function alleles.	Goetz et al. [10]
	ABCC2 / rs717620	In breast cancer patients positive for ER and/or PR, those with the CC genotype may experience a lower incidence of bone fractures when treated with the aromatase inhibitors anastrozole and exemestane, compared to those with CT or TT genotypes. Patients with the CT genotype face a higher fracture risk than those with CC but lower than those with TT. The TT genotype is associated with the highest fracture risk in these circumstances.	Insee et al. [11]
	ESR1 / rs9340799	Women carrying the AA genotype exhibit a less pronounced reduction in total cholesterol due to tamoxifen treatment in postmenopausal women and minor variations in triglycerides and HDL in premenopausal women, compared to those with the GG genotype. Those with the AG genotype display intermediate effects on postmenopausal total cholesterol and on triglycerides and HDL levels in premenopausal women, in comparison to the GG genotype. Individuals with the GG genotype experience a more significant decrease in total cholesterol in postmenopausal women and greater fluctuations in triglycerides and HDL in premenopausal women, in contrast to GA/AA genotypes.	Ntukidem et al. [12]
	ESR2 / rs4986938	In postmenopausal individuals, those possessing the CC genotype are likely to exhibit a notably higher increase in	Ntukidem et al. [12]

		triglyceride levels as a response to tamoxifen treatment, in contrast to those with TT or CT genotypes.	
	ZNF423 / rs8060157	Individuals carrying either the AA or AG genotypes might face a diminished risk of breast cancer onset while undergoing treatment with Selective Estrogen Receptor Modulators (SERMs), such as raloxifene or tamoxifen, relative to those with the GG genotype.	James et al. [13]
	Non-coding DNA / rs10030044	Patients with GG or GT genotypes have an increased risk of breast cancer when treated with Selective Estrogen Receptor Modulators (SERMs) like raloxifene or tamoxifen in breast neoplasms, compared to those with the TT genotype. Conversely, TT genotype carriers may have a decreased risk compared to GG genotype individuals.	James et al. [13]

123

## 124 **DISCUSSION**

125

126 In examining the role of pharmacogenetics in breast cancer treatment, it's essential to  
127 recognize the limitations of current genetic panels: they often lag behind the latest research  
128 developments and tend to focus on a narrow range of genetic variations. This approach can  
129 overlook critical genetic variations that have emerged as statistically significant, while still  
130 including those that have become less relevant [1]. Additionally, these studies predominantly  
131 target individuals of European descent, resulting in a lack of genetic diversity. This narrow  
132 focus can lead to research outcomes that do not adequately represent the entire global  
133 population, potentially limiting their applicability across various ethnic groups or individuals  
134 with diverse genetic backgrounds [14].

135

136 Another significant hurdle in the clinical adoption of pharmacogenetics is the associated high  
137 cost. Equipping and maintaining laboratories with the latest technology and skilled personnel  
138 to perform and interpret genetic testing, or outsourcing these services, presents a substantial  
139 financial challenge, especially for healthcare facilities in developing countries [15].

140

141 Despite its vast potential, pharmacogenetics encounters substantial obstacles, including the  
142 need for frequent updates to genetic panels to encompass a wider array of genes and the  
143 challenge of managing the high costs associated with this advanced technology and  
144 specialized training. Addressing these challenges is imperative for optimizing the use of  
145 personalized medicine in breast cancer treatment, ensuring it benefits patients from all ethnic  
146 and socioeconomic backgrounds.

147

## 148 **CONCLUSION**

149

150 Pharmacogenomics is applied to personalize first-line breast cancer treatments through the  
151 identification of genetic variations that impact the efficacy and side effects of drugs like  
152 Letrozole, Anastrozole, and Tamoxifen. This approach involves analyzing specific



153 genotypes, such as CYP19A1, CYP2A6, ESR1, ESR2, and UGT1A4 rs3732218, to  
154 understand their influence on drug metabolism and patient response. This methodology  
155 enables more accurate dose adjustments and treatment plans tailored to individual genetic  
156 profiles, thereby enhancing treatment effectiveness and reducing the risk of adverse effects.  
157 The study highlights the critical role of pharmacogenetics in advancing personalized  
158 medicine in breast cancer treatment, emphasizing the need for further research to explore the  
159 impact of various genetic variations on drug response.

160

## 161 REFERENCES

162

163 1. Tan, S.-H., Lee, S.-C., Goh, B.-C., & Wong, J. (2008). Pharmacogenetics in Breast Cancer  
164 Therapy. *Clinical Cancer Research*, 14(24), 8027-8041.

165

166 2. Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., &  
167 Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics  
168 knowledge for personalized medicine. *Clinical Pharmacology & Therapeutics*. [Online ahead  
169 of print].

170

171 3. Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F.,  
172 Altman, R. B., & Klein, T. E. (2012). Pharmacogenomics knowledge for personalized  
173 medicine. *Clinical Pharmacology & Therapeutics*, 92(4), 414-417.

174

175 4. Nagasubramanian, R., Innocenti, F., & Ratain, M. J. (2003). Pharmacogenetics in cancer  
176 treatment. *Annual Review of Medicine*, 54, 437-452. doi:  
177 10.1146/annurev.med.54.101601.152352.

178

179 5. Wong, Z.-W., & Ellis, M. J. (2004). First-line endocrine treatment of breast cancer:  
180 aromatase inhibitor or antioestrogen? *British Journal of Cancer*, 90, 20-25.

181

182 6. Liewei, W., Ellsworth, K. A., Moon, I., Pelleymounter, L., et al. (2010). Functional genetic  
183 polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to  
184 neoadjuvant therapy with aromatase inhibitors. *Cancer Research*.

185

186 7. Desta, Z., et al. (2011). Plasma letrozole concentrations in postmenopausal women with  
187 breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.  
188 *Clinical Pharmacology and Therapeutics*.

189

190 8. Oesterreich, S., et al. (2015). Associations between genetic variants and the effect of  
191 letrozole and exemestane on bone mass and bone turnover. *Breast Cancer Research and  
192 Treatment*.

193

194 9. Koroth, E. V., et al. (2013). Potential role of UGT1A4 promoter SNPs in anastrozole  
195 pharmacogenomics. *Drug Metabolism and Disposition: The Biological Fate of Chemicals*.

196

- 197 10. Goetz, M. P., Sangkuhl, K., Guchelaar, H.-J., et al. (2018). Clinical Pharmacogenetics  
198 Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. *Clinical*  
199 *Pharmacology & Therapeutics*.  
200
- 201 11. Insee, S., et al. (2016). ABCB1 and ABCC2 and the risk of distant metastasis in Thai  
202 breast cancer patients treated with tamoxifen. *OncoTargets and Therapy*.  
203
- 204 12. Ntukidem, N. I., et al. (2008). Estrogen receptor genotypes, menopausal status, and the  
205 lipid effects of tamoxifen. *Clinical Pharmacology and Therapeutics*.  
206
- 207 13. Ingle, J. N., et al. (2013). Selective estrogen receptor modulators and pharmacogenomic  
208 variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer  
209 prevention. *Cancer Discovery*.  
210
- 211 14. Patel, J. N. (2015). Cancer pharmacogenomics: implications on ethnic diversity and drug  
212 response. *Pharmacogenetics and Genomics*, 25(5), 223-230.  
213
- 214 15. Wong, W. B., Carlson, J. J., Thariani, R., & Veenstra, D. L. (2010). Cost effectiveness of  
215 pharmacogenomics: a critical and systematic review. [Journal name not provided], 28(11),  
216 1001-1013.